Renal Cancer
Immunotherapeutic Innovations in Clear Cell Renal Cell Carcinoma: Current Strategies and Future Directions.
September 9, 2024
Quadratus lumborum block for procedural and postprocedural analgesia in renal cell carcinoma percutaneous cryoablation.
September 6, 2024
Epigenetic modification of Castor zinc finger 1 (CASZ1) is associated with tumor microenvironments and prognosis of clear cell renal cell carcinoma.
September 6, 2024
Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical Trials.
September 5, 2024
Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab.
September 5, 2024
Randomized phase 2 dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma.
September 5, 2024
Renal cell carcinoma: entering the age of biomarkers.
September 4, 2024
Impact of DPP4 Inhibition on Survival in Patients With Metastatic Renal Cell Carcinoma and Type 2 Diabetes Mellitus.
September 2, 2024
KIR2DL2/DL3+NKs and Helios+Tregs in peripheral blood predict nivolumab response in patients with metastatic renal cell cancer.
September 2, 2024
Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer.
August 30, 2024
Contemporary Management of Renal Cell Carcinoma: A Review for General Practitioners in Oncology.
August 30, 2024
Renal Cell Carcinoma A Review
August 28, 2024